5 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Ductal adenocarcinoma is a rare type of prostate cancer, roughly one case in six hundred, that grows from the larger ducts of the gland rather than from its small acini. It tends to make less PSA than ordinary prostate cancer, so it is found later and more often after it has spread. It is treated with the same methods as ordinary prostate cancer and has no randomised trial of its own.
What it is. Ductal adenocarcinoma of the prostate is a carcinoma of the larger, more central prostatic ducts. Under the microscope it is built of tall columnar cells with stratified nuclei arranged in papillary, cribriform, glandular or solid patterns, in contrast to the cuboidal cells in small round acini that make up ordinary, acinar prostate cancer. The fifth edition of the WHO Classification of Tumours reserves the term ductal adenocarcinoma for radical prostatectomy specimens with more than 50 percent ductal morphology, and asks for the phrase 'adenocarcinoma with ductal features' on a needle biopsy whether the biopsy is pure ductal or mixed, because a needle sees too little of the gland to know the proportion.
How it differs from its parent. The fifth edition considered making ductal adenocarcinoma a subtype of acinar adenocarcinoma and decided against it, keeping it a separate type because of how differently it behaves (Kench 2022). It makes less PSA for the same amount of cancer: in a series of 371 ductal cases, ductal histology was associated with a 30 percent lower geometric mean PSA and more than twice the chance of a PSA under 4 ng/mL, independent of everything else. It presents more locally advanced (22.2 percent T3 against 8.9 percent for acinar on meta-analysis, relative risk 1.71 for T3 and 7.56 for T4) and with a 4.62 times higher relative risk of metastatic disease at diagnosis. It goes to places prostate cancer usually does not: lung, liver, brain, skin, penis, peritoneum and testis, which is why an unusual secondary tumour in a man with prostate cancer is a reason to look again at the histology.
| Setting | Approach | Guideline |
|---|---|---|
| Localised | Treated with the same methods as acinar prostate cancer: radical prostatectomy or radical radiotherapy. No randomised trial is specific to ductal histology, there is no consensus on the best treatment, and the retrospective comparisons of surgery against radiotherapy are small and inconsistent. | not mapped |
| Any stage, at diagnosis | Germline genetic testing is worth asking about. The NCCN recommends it in high-risk, regional or metastatic prostate cancer and says it should be considered in intermediate-risk disease with intraductal or cribriform histology (version 3.2024, as summarised in a 2025 review); ductal histology on its own is not named in the sources read, although it is commoner in people with inherited DNA-repair defects. | not mapped |
| Metastatic | Treated as metastatic acinar prostate cancer, with hormonal therapy with or without chemotherapy in the series reviewed. In the one study that asked the question, 35 ductal cases among 634 men with de novo metastatic prostate cancer had no worse overall or cancer-specific survival than acinar cases, so the histology's disadvantage appears to be in getting to metastasis sooner rather than in behaving worse once there. | not mapped |